Safinamide

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations

Overnight Switch From Rasagiline To Safinamide

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Independent, multicenter, phase IV, randomized, double-blind, parallel-group clinical trial in people with Parkinson's Disease under stable dopaminergic treatment with persistent fatigue symptoms, randomized 1:1 to adjunctive treatment with safinamide (100 mg/day) or rasagiline (1 mg/day) for 24 weeks.